FDAsafety guidance66% confidence
FDA AP — LUMVOA (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Viridian Therapeutics; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761530. Sponsor: VIRIDIAN THERAPEUTICS INC. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: VELIGROTUG-VVZE.
Supporting Context
- Therapeutic area
- Oncology · Monoclonal Antibody
- Sub-indication
- General
Related signal: FDA Approves BLA761530 (LUMVOA) from Viridian Therapeutics